Why the study?
Cardiovascular diseases remain leading causes of global mortality, prompting interest in evaluating the potential therapeutic applications of the CRISPR/Cas9 genome-editing tool for CVDs.
CRISPR/Cas9 represents a promising, highly efficient, and cost-effective genome-editing strategy for potential therapeutic applications in cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
CRISPR/Cas9 may enable future cardiovascular therapies; leaves open clinical translation pending rigorous trials.
Cardiovascular diseases (CVDs) remain major causes of global mortality in the world. Genetic approaches have succeeded in discovery of the molecular basis of an increasing number of cardiac diseases. Genome editing strategies are one of the most effective methods for assisting therapeutic approaches. Potential therapeutic methods of correcting disease-causing mutations or of knocking out specific genes as approaches for the prevention of CVDs have gained substantial attention using genome editing techniques. Recently, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system has become the most widely used genome-editing technology in molecular biology due to its benefits such as simple design, high efficiency, good repeatability, short-cycle, and costeffectiveness. In the present review, we discuss on the possibilities of applying the CRISPR/Cas9 genome editing tool in the CVDs.
No takes yet. Share an insight, caveat, or question.
Roshanravan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: